FDA approves diabetes drug indication to reduce CV risk
from Pharmacy Times
Officials with the FDA have approved a new indication for liraglutide (Victoza, Novo Nordisk), making it the only type 2 diabetes drug indicated to reduce the risk of major adverse cardiovascular events in adults, according to a press release from Novo. The approved indication is based on results from a clinical trial demonstrating that Victoza significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13 percent compared to a placebo, when added to standard care.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063